Nonsurgical management of ankylosing spondylitis

Jaypal Reddy Sangala, Elias Dakwar, Juan S. Uribe, Fernando Vale Diaz

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Object. The aim of this study was to review the current evidence-based nonsurgical management strategies of ankylosing spondylitis (AS) for spine surgeons. Whereas surgical management is indicated in a highly selected group, nonsurgical management is itself a useful measure for nearly all patients with AS. Methods. The authors conducted a literature review of PubMed using relevant search words. All the articles published in English in the last 15 years were reviewed and the level of evidence provided by them was noted. Results. Nonpharmacological treatments in the form of physical therapy and patient education have Level Ib evidence in maintaining function in AS.. There is Level Ib evidence supporting the use of nonsteroidal antiinflammatory drugs (NSAIDs) and coxibs for treatment in patients with symptoms. There is not enough evidence to support the Use of conventional disease-modifying antirheumatoid arthritis drugs. Tumor necrosis factor (TNF)α inhibitors (infliximab, etanercept, and adalimumab) are associated with Level Ib evidence in improving spinal pain, function, inflammatory biomarkers, and spinal inflammation detected by magnetic resonance imaging in patients in whom symptom duration has exceeded 3 months. Conclusions. Physical therapy and patient education are useful for all patients diagnosed vdth AS. If symptomatic, patients are started with either a course of nonselective NSAIDs or a selective cyclooxygenase-2 inhibitor. The role of NSAIDs as a disease-modifying therapy in the treatment of AS is increasingly being understood. The central role of TNF in the pathogenesis of AS is now known, and the advent of biological treatment in the form of anti-TNFα factors has revolutionized the medical management of AS and is used in patients with axial disease whose symptoms persist despite an adequate dose of NSAIDs.

Original languageEnglish (US)
Article numberE5
JournalNeurosurgical focus
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Ankylosing Spondylitis
Anti-Inflammatory Agents
Physical Education and Training
Pharmaceutical Preparations
Tumor Necrosis Factor-alpha
Cyclooxygenase 2 Inhibitors
Patient Education
Therapeutics
Tumor Necrosis Factors
PubMed
Arthritis
Spine
Biomarkers
Magnetic Resonance Imaging
Inflammation
Pain

Keywords

  • Ankylosing spondylitis
  • Nonsurgical management
  • Pharmacological therapy
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Nonsurgical management of ankylosing spondylitis. / Sangala, Jaypal Reddy; Dakwar, Elias; Uribe, Juan S.; Vale Diaz, Fernando.

In: Neurosurgical focus, Vol. 24, No. 1, E5, 01.01.2008.

Research output: Contribution to journalReview article

Sangala, Jaypal Reddy ; Dakwar, Elias ; Uribe, Juan S. ; Vale Diaz, Fernando. / Nonsurgical management of ankylosing spondylitis. In: Neurosurgical focus. 2008 ; Vol. 24, No. 1.
@article{8d407566ae214029b8f5e627f1130b3d,
title = "Nonsurgical management of ankylosing spondylitis",
abstract = "Object. The aim of this study was to review the current evidence-based nonsurgical management strategies of ankylosing spondylitis (AS) for spine surgeons. Whereas surgical management is indicated in a highly selected group, nonsurgical management is itself a useful measure for nearly all patients with AS. Methods. The authors conducted a literature review of PubMed using relevant search words. All the articles published in English in the last 15 years were reviewed and the level of evidence provided by them was noted. Results. Nonpharmacological treatments in the form of physical therapy and patient education have Level Ib evidence in maintaining function in AS.. There is Level Ib evidence supporting the use of nonsteroidal antiinflammatory drugs (NSAIDs) and coxibs for treatment in patients with symptoms. There is not enough evidence to support the Use of conventional disease-modifying antirheumatoid arthritis drugs. Tumor necrosis factor (TNF)α inhibitors (infliximab, etanercept, and adalimumab) are associated with Level Ib evidence in improving spinal pain, function, inflammatory biomarkers, and spinal inflammation detected by magnetic resonance imaging in patients in whom symptom duration has exceeded 3 months. Conclusions. Physical therapy and patient education are useful for all patients diagnosed vdth AS. If symptomatic, patients are started with either a course of nonselective NSAIDs or a selective cyclooxygenase-2 inhibitor. The role of NSAIDs as a disease-modifying therapy in the treatment of AS is increasingly being understood. The central role of TNF in the pathogenesis of AS is now known, and the advent of biological treatment in the form of anti-TNFα factors has revolutionized the medical management of AS and is used in patients with axial disease whose symptoms persist despite an adequate dose of NSAIDs.",
keywords = "Ankylosing spondylitis, Nonsurgical management, Pharmacological therapy, Tumor necrosis factor",
author = "Sangala, {Jaypal Reddy} and Elias Dakwar and Uribe, {Juan S.} and {Vale Diaz}, Fernando",
year = "2008",
month = "1",
day = "1",
doi = "10.3171/FOC/2008/24/1/E5",
language = "English (US)",
volume = "24",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Nonsurgical management of ankylosing spondylitis

AU - Sangala, Jaypal Reddy

AU - Dakwar, Elias

AU - Uribe, Juan S.

AU - Vale Diaz, Fernando

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Object. The aim of this study was to review the current evidence-based nonsurgical management strategies of ankylosing spondylitis (AS) for spine surgeons. Whereas surgical management is indicated in a highly selected group, nonsurgical management is itself a useful measure for nearly all patients with AS. Methods. The authors conducted a literature review of PubMed using relevant search words. All the articles published in English in the last 15 years were reviewed and the level of evidence provided by them was noted. Results. Nonpharmacological treatments in the form of physical therapy and patient education have Level Ib evidence in maintaining function in AS.. There is Level Ib evidence supporting the use of nonsteroidal antiinflammatory drugs (NSAIDs) and coxibs for treatment in patients with symptoms. There is not enough evidence to support the Use of conventional disease-modifying antirheumatoid arthritis drugs. Tumor necrosis factor (TNF)α inhibitors (infliximab, etanercept, and adalimumab) are associated with Level Ib evidence in improving spinal pain, function, inflammatory biomarkers, and spinal inflammation detected by magnetic resonance imaging in patients in whom symptom duration has exceeded 3 months. Conclusions. Physical therapy and patient education are useful for all patients diagnosed vdth AS. If symptomatic, patients are started with either a course of nonselective NSAIDs or a selective cyclooxygenase-2 inhibitor. The role of NSAIDs as a disease-modifying therapy in the treatment of AS is increasingly being understood. The central role of TNF in the pathogenesis of AS is now known, and the advent of biological treatment in the form of anti-TNFα factors has revolutionized the medical management of AS and is used in patients with axial disease whose symptoms persist despite an adequate dose of NSAIDs.

AB - Object. The aim of this study was to review the current evidence-based nonsurgical management strategies of ankylosing spondylitis (AS) for spine surgeons. Whereas surgical management is indicated in a highly selected group, nonsurgical management is itself a useful measure for nearly all patients with AS. Methods. The authors conducted a literature review of PubMed using relevant search words. All the articles published in English in the last 15 years were reviewed and the level of evidence provided by them was noted. Results. Nonpharmacological treatments in the form of physical therapy and patient education have Level Ib evidence in maintaining function in AS.. There is Level Ib evidence supporting the use of nonsteroidal antiinflammatory drugs (NSAIDs) and coxibs for treatment in patients with symptoms. There is not enough evidence to support the Use of conventional disease-modifying antirheumatoid arthritis drugs. Tumor necrosis factor (TNF)α inhibitors (infliximab, etanercept, and adalimumab) are associated with Level Ib evidence in improving spinal pain, function, inflammatory biomarkers, and spinal inflammation detected by magnetic resonance imaging in patients in whom symptom duration has exceeded 3 months. Conclusions. Physical therapy and patient education are useful for all patients diagnosed vdth AS. If symptomatic, patients are started with either a course of nonselective NSAIDs or a selective cyclooxygenase-2 inhibitor. The role of NSAIDs as a disease-modifying therapy in the treatment of AS is increasingly being understood. The central role of TNF in the pathogenesis of AS is now known, and the advent of biological treatment in the form of anti-TNFα factors has revolutionized the medical management of AS and is used in patients with axial disease whose symptoms persist despite an adequate dose of NSAIDs.

KW - Ankylosing spondylitis

KW - Nonsurgical management

KW - Pharmacological therapy

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=41949107680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949107680&partnerID=8YFLogxK

U2 - 10.3171/FOC/2008/24/1/E5

DO - 10.3171/FOC/2008/24/1/E5

M3 - Review article

C2 - 18290743

AN - SCOPUS:41949107680

VL - 24

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 1

M1 - E5

ER -